PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis (NCT06422871)
PReSeRVE-HD: PRospective, Multicenter, Observational Study of the Merit HeRO® Graft and Super HeRO® EValuated in End-Stage Renal Disease Patients on HemoDialysis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit during the 4 visit timepoints over 2 years, the participant will be followed by phone to check their current health and dialysis status.
Who can join: Review the eligibility criteria below.
Location: MedStar Washington Hospital Center — Washington D.C., District of Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sarasota Memorial Health Care System — Sarasota, Florida
- WakeMed — Raleigh, North Carolina
- University Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Baylor Scott & White Heart and Vascular Hospital - Dallas — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- Sentara Norfolk General Hospital — Norfolk, Virginia
📞 Contact the Study Coordinator
Phone: (978) 758-6166
Email: Hannah.Susmeyer@merit.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End Stage Renal Disease
- Light Therapy in End Stage Kidney Disease — Philadelphia, Pennsylvania
- Ferric Citrate in ESRD Pilot Project — Houston, Texas
- Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients — Washington D.C., District of Columbia
- Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease — New York, New York
- Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis — San Antonio, Texas
Explore by condition: All End Stage Renal Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.